Yasushi Okuno

Yasushi Okuno

Auto-generated profile, based on publicly available information

Yasushi Okuno

Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KMKen Morita
Ken Morita
KSKensho Suzuki
Kensho Suzuki
SMShintaro Maeda
Shintaro Maeda
AMAkihiko Matsuo
Akihiko Matsuo
YMYoshihide Mitsuda
Yoshihide Mitsuda
YKYasuhiko Kamikubo
Yasuhiko Kamikubo
Runt-related transcription factor 1 (RUNX1) is generally considered to function as a tumor suppressor in the development of leukemia, but a growing body of evidence suggests that it has pro-oncogenic properties in acute myeloid leukemia (AML). Here we have demonstrated that the antileukemic effect mediated by RUNX1 depletion is highly dependent on a functional p53-mediated cell death pathway. Increased expression of other RUNX family members, including RUNX2 and RUNX3, compensated for the antitumor effect elicited by RUNX1 silencing, and simultaneous attenuation of all RUNX family members as a cluster led to a much stronger antitumor effect relative to suppression of individual RUNX members. Switching off the RUNX cluster using alkylating agent–conjugated pyrrole-imidazole (PI) polyamides, which were designed to specifically bind to consensus RUNX-binding sequences, was highly effective against AML cells and against several poor-prognosis solid tumors in a xenograft mouse model of AML without notable adverse events. Taken together, these results identify a crucial role for the RUNX cluster in the maintenance and progression of cancer cells and suggest that modulation of the RUNX cluster using the PI polyamide gene-switch technology is a potential strategy to control malignancies.

24 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HMHayato Mizuta
Hayato Mizuta
KOKoutaroh Okada
Koutaroh Okada
MAMitsugu Araki
Mitsugu Araki
JAJun Adachi
Jun Adachi
ATAi Takemoto
Ai Takemoto
RKRyohei Katayama
Ryohei Katayama
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified from the patients, and several compound mutations, such as I1171N + F1174I or I1171N + L1198H are resistant to all the approved ALK-TKIs. In this study, we found that gilteritinib has an inhibitory effect on ALK-TKI–resistant single mutants and I1171N compound mutants in vitro and in vivo. Surprisingly, EML4-ALK I1171N + F1174I compound mutant-expressing tumors were not completely shrunk but regrew within a short period of time after alectinib or lorlatinib treatment. However, the relapsed tumor was markedly shrunk after switching to the gilteritinib in vivo model. In addition, gilteritinib was effective against NTRK-rearranged cancers including entrectinib-resistant NTRK1 G667C-mutant and ROS1 fusion-positive cancer.

1 May 2008 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HKHiroaki Kawanishi
Hiroaki Kawanishi
YMYoshiyuki Matsui
Yoshiyuki Matsui
MIMasaaki Ito
Masaaki Ito
JWJun Watanabe
Jun Watanabe
TTTakeshi Takahashi
Takeshi Takahashi
OOOsamu Ogawa
Osamu Ogawa
Purpose: The purpose of this study was to identify proteins that are potentially involved in the tumor invasion of bladder cancer. Experimental Design: We searched for the candidate proteins by comparing the profiles of secreted proteins among the poorly invasive human bladder carcinoma cell line RT112 and the highly invasive cell line T24. The proteins isolated from cell culture supernatants were identified by shotgun proteomics. We found that CXCL1 is related to the tumor invasion of bladder cancer cells. We also evaluated whether the amount of the chemokine CXCL1 in the urine would be a potential marker for predicting the existence of invasive bladder tumors. Results: Higher amount of CXCL1 was secreted from highly invasive bladder carcinoma cell lines and this chemokine modulated the invasive ability of those cells in vitro. It was revealed that CXCL1 regulated the expression of matrix metalloproteinase-13 in vitro and higher expression of CXCL1 was associated with higher pathologic stages in bladder cancer in vivo. We also showed that urinary CXCL1 levels were significantly higher in patients with invasive bladder cancer (pT1-4) than those with noninvasive pTa tumors (P = 0.0028) and normal control (P < 0.0001). Finally, it was shown that CXCL1 was an independent factor for predicting the bladder cancer with invasive phenotype. Conclusions: Our results suggest that CXCL1 modulates the invasive abilities of bladder cancer cells and this chemokine may be a potential candidate of urinary biomarker for invasive bladder cancer and a possible therapeutic target for preventing tumor invasion.

1 September 2020 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
EUEiichiro Uchino
Eiichiro Uchino
KSKanata Suzuki
Kanata Suzuki
NSNoriaki Sato
Noriaki Sato
RKRyosuke Kojima
Ryosuke Kojima
YTYoshinori Tamada
Yoshinori Tamada
YOYasushi Okuno
Yasushi Okuno

30 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
RHRyusuke Hatae
Ryusuke Hatae
KCKenji Chamoto
Kenji Chamoto
YKYoung-Hoon Kim
Young-Hoon Kim
KSKazuhiro Sonomura
Kazuhiro Sonomura
KTKei Taneishi
Kei Taneishi
THTasuku Honjo
Tasuku Honjo
BACKGROUND: Current clinical biomarkers for the programmed cell death 1 (PD-1) blockade therapy are insufficient because they rely only on the tumor properties, such as programmed cell death ligand 1 expression frequency and tumor mutation burden. Identifying reliable, responsive biomarkers based on the host immunity is necessary to improve the predictive values. METHODS: We investigated levels of plasma metabolites and T cell properties, including energy metabolism markers, in the blood of patients with non-small cell lung cancer before and after treatment with nivolumab ( n = 55). Predictive values of combination markers statistically selected were evaluated by cross-validation and linear discriminant analysis on discovery and validation cohorts, respectively. Correlation between plasma metabolites and T cell markers was investigated. RESULTS: The 4 metabolites derived from the microbiome (hippuric acid), fatty acid oxidation (butyrylcarnitine), and redox (cystine and glutathione disulfide) provided high response probability (AUC = 0.91). Similarly, a combination of 4 T cell markers, those related to mitochondrial activation (PPARγ coactivator 1 expression and ROS), and the frequencies of CD8 + PD-1 hi and CD4 + T cells demonstrated even higher prediction value (AUC = 0.96). Among the pool of selected markers, the 4 T cell markers were exclusively selected as the highest predictive combination, probably because of their linkage to the abovementioned metabolite markers. In a prospective validation set ( n = 24), these 4 cellular markers showed a high accuracy rate for clinical responses of patients (AUC = 0.92). CONCLUSION: Combination of biomarkers reflecting host immune activity is quite valuable for responder prediction. FUNDING: AMED under grant numbers 18cm0106302h0003, 18gm0710012h0105, and 18lk1403006h0002; the Tang Prize Foundation; and JSPS KAKENHI grant numbers JP16H06149, 17K19593, and 19K17673.

4 February 2021 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
SMShigeyuki Matsumoto
Shigeyuki Matsumoto
SIShoichi Ishida
Shoichi Ishida
MAMitsugu Araki
Mitsugu Araki
TKTakayuki Kato
Takayuki Kato
KTKei Terayama
Kei Terayama
YOYasushi Okuno
Yasushi Okuno